MBX Biosciences, Inc.

Historical 13F Holders

Symbol
MBX
CUSIP
55287L101
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 55287L101 since 12/18/2024, largest first.

Filer % of Class Filed
FMR LLC 13G/A
15.0% 11/5/2026
Event 9/30/2026
Frazier Life Sciences Public Fund, L.P. 13D/A
11.7% 8/10/2026
Event 8/6/2026
Wellington Management Group LLP 13G/A
10.5% 7/8/2026
Event 6/30/2026
New Enterprise Associates 17, L.P. 13D/A
8.1% 11/10/2025
Event 11/6/2025
Paradigm Biocapital Advisors LP 13G/A
7.8% 11/16/2026
Event 9/30/2026
Orbimed Advisors LLC 13D/A
6.4% 8/10/2026
Event 8/6/2026
BlackRock, Inc. 13G 5.5% 7/29/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Norwest Venture Partners XVI, LP 13D/A
4.8% 9/30/2025
Event 9/26/2025
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 13G/A 4.5% 11/12/2025
Event 9/30/2025
P. Kent Hawryluk 13G/A 4.3% 11/14/2025
Event 9/30/2025
Deep Track Capital, LP 13G/A
3.6% 8/14/2026
Event 6/30/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 192 55.5 M $3.25B
2026 Q2 175 55.5 M $3.06B
2026 Q1 158 52.5 M $1.57B
2025 Q4 140 48.4 M $1.53B
2025 Q3 124 47.8 M $836M
2025 Q2 90 36.8 M $420M
2025 Q1 80 35.7 M $263M
2024 Q4 64 32.9 M $606M
2024 Q3 46 30.3 M $784M